HealthPersonalised mRNA vaccine cuts melanoma recurrence or death risk by 42 percent in trial
In Merck and Moderna's phase 3 trial of 1,137 melanoma patients, those given the vaccine had a 42 percent lower combined risk of the cancer returning or death within two years; whether it extends survival is not yet known.